Learning objectives:

After watching this webinar, participants will understand: 

• why it is important to identify tricuspid regurgitation and how to diagnose, evaluate, and treat it; 
• the body of evidence supporting therapy value with a focus on clinical outcomes; 
• which patients can benefit from transcatheter tricuspid valve repair; and 
• how to evaluate the tricuspid valve (echo screening guidance) and how to define patient echo eligibility.

Needs assessment and expected educational outcome:

To understand expanding transcatheter treatment options for patients suffering from tricuspid regurgitation by reviewing clinical outcomes from the TRILUMINATE trial and by delving into real-world data of the TriClip bRIGHT Study documenting repairs using the Abbott TriClip device. This body of evidence is mentioned in the 2020 ACC Guidelines and in the new 2021 ESC/EACTS/HF Guidelines. 

Main topic

• VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE

Related Topic

• Valvular Heart Disease

Session information:

This webinar is designed for all cardiologists interested by Valvular Heart Disease (including Heart Failure, Interventionalist, Imaging specialist, Surgeon).

During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.

An application has been made to the EACCME® for CME accreditation of this event.

Technical settings:

The webinar is available on PC and tablets. The use of a smartphone is not recommended.

To answer the MCQs during the live, you must allow pop-up windows.

A high-speed Internet connection is required (minimum 2 Mbps).